

Biochemistry. Author manuscript; available in PMC 2010 February 10.

Published in final edited form as:

Biochemistry. 2009 February 10; 48(5): 863-872. doi:10.1021/bi801595t.

# Reaction of *Mycobacterium tuberculosis* Cytochrome P450 Enzymes with Nitric Oxide†

Hugues Ouellet<sup>‡</sup>, Jérôme Lang<sup>§</sup>, Manon Couture<sup>§</sup>, and Paul R. Ortiz de Montellano<sup>\*,‡</sup> Department of Pharmaceutical Chemistry, University of California, San Francisco, California 94158-2517, Department of Biochemistry and Microbiology, Laval University, Quebec, Canada, G1K 7P4

# **Abstract**

During the initial growth infection stage of *Mycobacterium tuberculosis (Mtb)*, \*NO produced by host macrophages inhibits heme-containing terminal cytochrome oxidases, inactivates iron/sulfur proteins and promotes entry into latency. Here we evaluate the potential of \*NO as an inhibitor of *Mtb* cytochrome P450 enzymes, as represented by CYP130, CYP51 and the two previously uncharacterized enzymes CYP125 and CYP142. Using UV-visible absorption, resonance Raman, and stopped-flow spectroscopy, we investigated the reactions of \*NO with these hemeproteins in their ferric resting form. \*NO coordinates tightly to CYP125 and CYP142 (submicromolar), and with a lower affinity (micromolar) to CYP130 and CYP51. Anaerobic reduction of the ferric-NO species with sodium dithionite led to the formation of two spectrally distinct classes of five-coordinate ferrous-NO complexes. Exposure of these species to  $O_2$  revealed that the ferrous-NO forms of CYP125 and CYP142 are labile and convert back to the ferric state within a few minutes, whereas ferrous CYP130 and CYP51 bind \*NO almost irreversibly. This work clearly indicates that, at physiological concentrations ( $\approx 1~\mu\text{M}$ ), \*NO would impair the activity of CYP130 and CYP51, whereas CYP125 and CYP142 are more resistant. Selective P450 inhibition may contribute to the inhibitory effects of \*NO on *Mtb* growth.

Mycobacterium tuberculosis (Mtb)<sup>1</sup> continues to be an enormous threat to human health. Indeed, Mtb infects over 1.8 billion people worldwide and causes 1.5 million deaths per year. In immunocompetent individuals, the innate and adaptive arms of the immune system are relatively efficient in containing and killing Mtb. It is estimated that of 100 people newly infected with the tubercle bacilli, only about 5-10 individuals will develop tuberculosis over their lifetime (1). Host cells that are protective against Mtb include macrophages, dendritic cells, T-lymphocytes, and airway epithelial cells (2). The production of reactive oxygen intermediates and reactive nitrogen intermediates by innate immune cells is considered to be

SUPPORTING INFORMATION AVAILABLE The list of PCR primers for the cloning of *cyp* genes studied here are provided in Table S1. Spectral data from the reduction of ferric P450 enzymes by sodium dithionite in the absence or presence of CO are presented in Figure S1 and S2. The wavelength maxima of the calculated spectra and kinetic rates obtained from the reduction of the ferric and ferric-nitrosyl derivatives by sodium dithionite are listed in Tables S2 to S7. Selected representive real spectra from the reduction of the ferric-NO complexes by sodium dithionite are shown in Figure S3. Table S8 lists the wavelength maxima of the electronic absorption spectra of the ferric- and ferrous-nitrosyls complexes of selected thiolate-ligated hemeproteins. A list of relevant references is also provided with Table S8. Figure S4 presents the oxidation of ferrous-nitrosyl complexes in the presence of O2. This material is available free of charge via the Internet at http://pubs.acs.org.

<sup>\*</sup>To whom correspondence should be addressed. Telephone: (415) 476-2903. Fax: (415) 502-4728. E-mail: E-mail: ortiz@cgl.ucsf.edu.. \*University of California at San Francisco

<sup>§</sup>Laval University

<sup>&</sup>lt;sup>1</sup>Abbreviations: *Mtb*, *Mycobacterium tuberculosis*; RNI, reactive nitrogen intermediates; P450, cytochrome P450; 5c, five-coordinate; 6c, six-coordinate; NOS, nitric oxide synthase; nNOS, neuronal isoform of NOS; iNOS, inducible isoform of NOS; eNOS, endothelial isoform of NOS.

a relatively effective host-defense mechanism against microbial pathogens (3). For instance, exposure to  ${}^{\bullet}$ NO at low concentrations, *e.g.*, < 100 ppm, killed more than 99% of *Mtb* in culture (4).

The potential mechanisms by which 'NO may affect antimicrobial activity are numerous. 'NO and other reactive nitrogen intermediates (RNI) can modify bacterial DNA, protein, and lipids at both the microbial surface and intracellularly. 'NO can also deaminate as well as directly damage bacterial DNA, generating abasic sites and strand breaks (5). Other potential mechanisms of killing by 'NO include interaction with accessory protein targets such as ironsulfur groups, heme group and thiols, resulting in enzymatic inactivation or other protein malfunctions (6). 'NO also combines at a near diffusion-limited rate with superoxide produced by respiring cells to form the highly oxidizing agent peroxynitrite (7). Peroxynitrite can mediate nitration of tyrosine residues, and therefore has a potential, for instance, of disrupting tyrosine phosphorylation-dependent signaling pathways (8).

A number of studies has implicated 'NO as a mediator responsible for the decrease of cytochrome P450-dependent metabolism in human liver (9,10) and suggests that the binding of NO to the prosthetic heme of the enzyme might inhibit bacterial cytochrome P450 (P450) activities as well. Sequencing of the Mtb genome revealed the existence of an extraordinary array of 20 P450 enzymes, all of which are potential targets for inhibition by 'NO (11) and at least several of which are essential for bacterial survival or pathogenicity. The location of P450encoding genes on the Mtb chromosome provides little insight into their biological function, but physiological roles have been proposed for a few Mtb P450s, including a role in fatty acid metabolism for CYP132 and in mycolic acid or polyketide metabolism for CYP121 (12). Mtb CYP51, like its eukaryotic homologs, catalyzes  $14\alpha$ -demethylation of lanosterol (13). However, there is no evidence for the presence of a complete sterol biosynthetic pathway in Mtb. Instead, CYP51 may be involved in the metabolism of a host steroid. CYP142 and CYP125 are of particular interest because they are part of a chromosomal DNA region found in the genome of Mtb and a related actinomycete Rhodococcus sp. strain RHA1. This large regulon, which bears several genes potentially involved in the degradation of lipids such as cholesterol, has been reported to be essential for host infection by Mtb (14). Moreover, CYP125 was recently shown to be essential for infection in mice and is induced within the macrophage (15,16). To date, only CYP121, CYP130 and CYP51 have been characterized at the protein level, and crystal structures have been obtained for both the ligand-free and inhibitor-bound forms of these three proteins (17-20).

In this work, we report for the first time cloning and expression of the *Mtb cyp125* and *cyp142* genes in *Escherichia coli* cells, leading to the purification and preliminary characterization of these new P450 enzymes. Ferric CYP142, CYP125, and CYP51, reversibly bind 'NO with moderate to high affinity, making them plausible targets for this natural inhibitor. The reduction of the ferric-NO complexes resulted in the formation of two classes of ferrous-NO complexes that exhibit different reactivity upon exposure to O<sub>2</sub>. Indeed, we show here that CYP130, and to a smaller extent CYP51, are susceptible to almost irreversible inhibition by 'NO, whereas CYP142 and CYP125 are more resistant to the conditions found in activated macrophages, in which •NO and O<sub>2</sub> are simultaneously present.

## **EXPERIMENTAL PROCEDURES**

## **Materials**

Econazole, glucose, glucose oxidase from *Aspergillus niger*, bovine liver catalase and horse heart myoglobin were purchased from Sigma-Aldrich.

## Molecular cloning of cyp125, cyp142 and cyp51 genes

Genomic DNA from *Mtb* H37Rv was obtained from the TB research materials available at Colorado State University (http://www.cvmbs.colostate.edu/microbiology/tb/materials.htm). The DNA regions encoding the putative CYP125 and CYP142 were amplified by PCR using *Pfu* Turbo DNA polymerase (Stratagene) and primers listed in Table S1 (supporting material). The amplification conditions were 94 °C for 5 min, 5 cycles of 94 °C for 30 s, 55 °C for 30 s, and 72 °C for 3 min followed by 25 cycles of 94 °C for 30 s, 65 °C for 30 s, and 72 °C for 3 min. The PCR program was ended by a polymerization step at 72 °C for 25 min. To confirm the DNA sequences, PCR fragments were first cloned into pCR2.1 TOPO vector (Invitrogen) and then the *Nde I-Hind III* digested fragments were sub-cloned into a modified pCW vector (21), which allows the expression of recombinant proteins with an N-terminal 6xHis-tag.

## Expression of Mtb P450s in Escherichia coli cells

Recombinant *Mtb* CYP51, CYP125, CYP130 and CYP142 were expressed in *E. coli* DH5 $\alpha$  cells and purified according to a previously described protocol (18). The concentration of P450 was determined from difference spectra using the extinction coefficient  $\epsilon_{450-490} = 91,000$  M<sup>-1</sup> cm<sup>-1</sup> (22).

#### **Anaerobic Conditions**

Sample preparation for UV-vis spectroscopy and stopped-flow spectrophotometric experiments to be carried out under anaerobic conditions was performed in a glovebox (UniLab, MBraun Inc.) equipped with a catalytic purifier that maintained the oxygen content at  $\leq 3$  ppm. To reproducibly maintain satisfactorily strict anaerobic conditions, the sample-handling unit of the stopped-flow spectrophotometer was treated for at least 2 h with a glucose oxidase/catalase  $O_2$ -removing system consisting of 2 U/ml of glucose oxidase, 10 mM glucose and 130 U/ml of catalase).

## Optical absorption spectroscopy

UV-visible absorption spectra of the purified proteins in buffer were recorded on a Cary UV-visible scanning spectrophotometer (Varian) using a 1-cm path length quartz cuvette at 23 °C. The ferric-NO species was obtained in strict anaerobic conditions as described above and by flushing the head-space of the cuvette with Ar (Airgas, CA) for 15 min followed by pure \*NO gas (Matheson Tri Gas, CA) for 30 s.

## Stopped-flow spectrophotometry

Rapid mixing experiments were conducted with a Hi-Tech Scientific instrument (Bradford on Avon, UK) equipped with a photodiode array detector. All the reaction kinetics were measured at 23 °C, unless otherwise specified. Kinetic data were analyzed using the Specfit/32 program (Spectrum Software Ass. USA). The kinetic constants obtained from the fitting had uncertainties of  $\leq$ 5%.

#### 'NO combination Rate

Solutions of ferric Mtb P450s (5  $\mu$ M) were mixed rapidly with buffered-solutions of \*NO (50-2000  $\mu$ M), and the reaction was followed at 437 and 418 nm, a maximum and minimum, respectively, in the Fe<sup>3+</sup>-NO form *minus* Fe<sup>3+</sup> form difference spectrum. At least six \*NO concentrations were used.

## 'NO dissociation rate

Solutions of ferric-NO Mtb P450s (10  $\mu$ M heme, 20  $\mu$ M  $^{\circ}$ NO) were mixed rapidly with a solution of ferrous-O<sub>2</sub> myoglobin (Mb-O<sub>2</sub>, 25  $\mu$ M). The reaction was followed by photo-diode

array spectroscopy over very short (0.9 s) and long (450 s) time scales. Mb-O $_2$  was prepared in the glovebox by reducing the ferric form with 5 molar equivalents of sodium dithionite for 5 min. The ferrous deoxy protein was next passed onto a size-exclusion column (PD10, Amersham Biosciences) equilibrated with anaerobic buffer to remove excess of sodium dithionite. The eluted ferrous Mb was diluted at a final concentration of 25  $\mu$ M with air-saturated buffer.

#### Reduction of ferric-NO Mtb P450s with dithionite

Solutions of ferric-NO Mtb P450s (5  $\mu$ M heme plus 100  $\mu$ M  $^{\circ}$ NO) were reacted with an anaerobic solution of sodium dithionite (250  $\mu$ M). A total of 200 spectra were recorded over different time scales up to 2225 s.

## Resonance Raman spectra

The equipment used to acquire the resonance Raman spectra has been described previously (23). The spectra of the ferrous-NO complexes, were obtained with the 413-nm line of a krypton ion laser (Innova 302 laser, Coherent, Santa Clara, CA, U.S.A.). Typically, several 1 min spectra were recorded with a low excitation power (3-4 mW) at room temperature and averaged with Grams software (ThermoGalactic, Salem, NH, U.S.A.). The spectra were calibrated with the lines of indene in the 200-1900 cm $^{-1}$  region. To verify the stability of the samples, optical spectra of the samples in the Raman cuvette were recorded prior to and after the resonance Raman spectra were obtained. Typically, samples containing 30-40  $\mu$ M protein, based on the P450 content, were used to acquire the resonance Raman spectra.

## **RESULTS**

## Expression and purification of CYP125 and CYP142

Using a pCW vector, the previously uncharacterized CYP125 and CYP142 proteins were expressed in *E. coli* in good yields. The proteins were purified to apparent homogeneity by Ni<sup>2+</sup>-affinity and anion-exchange Q-sepharose chromatography. The yields after purification, as estimated by P450 content, were ~125 and 1250 nmols per liter of culture for CYP125 and CYP142, respectively.

## **UV-visible absorption spectroscopy**

The UV-visible absorption spectra of different ferric forms of CYP130, CYP51 and the two previously uncharacterized proteins CYP125 and CYP142 are presented in Figure 1. The resting form of CYP125 exists mostly in the high-spin state, as evidenced by a Soret band at 392 nm and the presence of a charge transfer band (CT) at 643 nm (Figure 1A). A shoulder at 419 nm indicates the presence of a small but significant fraction of low-spin heme. In contrast, CYP142, CYP130 and CYP51 were purified from  $E.\ coli$  in the ferric form with the heme iron in the low-spin state with a water molecule as the probable sixth ligand, as evidenced by a Soret band located at 418 nm and  $\alpha$  and  $\beta$  bands at 567 and 535 nm, respectively (Figure 1B-D).

The addition of the antifungal azole agent econazole to all the proteins except CYP125 resulted in the expected type-II spectral shift in which the N $\epsilon$ 1 atom of the azole group coordinates to the heme iron (Figure 1B-D). In contrast, the binding of econazole to CYP125 caused a complete transition to the high-spin state, as evidenced by sharper Soret and CT bands at 390 and 643 nm, respectively (Figure 1A). The bubbling of  ${}^{\bullet}$ NO to solutions of ferric proteins prepared in strictly anaerobic conditions resulted for all proteins in the formation of nitrosyl complexes characterized by Soret,  $\alpha$  and  $\beta$  bands located at 433, 572 and 541 nm, respectively.

#### 'NO combination

The combination rates for \*NO binding to Mtb CYP125, CYP130, CYP142 and CYP51 were measured by stopped-flow spectrophotometry. As a representative set of data for all four P450 enzymes, Figure 2 shows the time courses at 433 nm as a function of increasing \*NO concentration for CYP51. The reactions of CYP51, CYP125 and CYP130 with \*NO were nearly monophasic and the observed pseudo-first-order rate constants increase linearly with the \*NO concentration (Figure 3A-C). On the other hand, the time course of \*NO combination with CYP142 was better fitted to a double exponential function and two distinct sets of pseudo-first-order rate constants were obtained (Figure 3C). The second-order association rate constants ( $k'_{on}$ ) calculated from the slopes of these plots are summarized in Table 1. Remarkably, the  $k'_{on}$  values range from 0.2 to 17.1  $\mu$ M<sup>-1</sup>·s<sup>-1</sup>, indicating that these proteins possess very different active site architectures. This biphasic behavior of the CYP142 kinetics can be interpreted in terms of an equilibrium between CYP142 conformational substates.

#### 'NO dissociation

The rate of 'NO dissociation for the four Mtb P450s was measured by mixing the ferric-NO complexes with Mb-O<sub>2</sub>. By this approach, both free 'NO and 'NO released from ferric nitrosyl complexes were instantly converted into nitrate through the NO-dioxygenase activity of Mb-O<sub>2</sub>. In a control experiment, in which Mb-O<sub>2</sub> was rapidly mixed with the same total concentration of free 'NO, we confirmed that the scavenging action of Mb-O<sub>2</sub> is very efficient (>  $500 \, \text{s}^{-1}$ ) and outcompetes the release of 'NO from our four Mtb P450s (Figure 4, Inset). The kinetics of oxidation of Mb-O<sub>2</sub> due to the 'NO released from P450-NO complexes was monitored at 433 nm and satisfactorily fitted to a single exponential, as shown in Figure 4. The observed rates are summarized in Table 1. The  $k_{\text{off}}$  values for CYP130, CYP142 and CYP51 are higher than that of camphor-free CYP101, but are similar to that of camphor-bound CYP101. On the other hand, the  $k_{\text{off}}$  value for CYP125 is higher than that of CYP101 and approaches the value of human inducible nitric oxide synthase (iNOS).

## Reduction of ferric-NO complex with sodium dithionite

We unsuccessfully attempted to measure 'NO binding kinetic constants in the ferrous state in the absence of dithionite. Indeed, we first investigated the reduction of the ferric Mtb P450s by sodium dithionite and the stability of the resulting ferrous deoxy and ferrous-CO derivatives by stopped-flow spectrophotometry. Figures S1 and S2 (supporting material) present the calculated species obtained after singular value decomposition (SVD) and global analysis of the spectral data collected in the absence or presence of CO. The wavelength maxima of the different calculated species and all derived rate constants are summarized in Tables S2 to S5 (supporting material). Although the reduction rate is very slow, CYP125 and CYP142 exhibit stable ferrous deoxy and ferrous-CO species (Figure S1 and S2, panels A and B). However, the preparation of the ferrous deoxy form of these two proteins is not only time-consuming but technically unfeasible due to the very high tendency to autooxidize after removal of the excess of sodium dithionite by gel filtration chromatography (not shown). For CYP130 and CYP51, the reduction rate is not really a limiting factor but these two proteins exhibit moderate to high instability in the ferrous state, as evidenced by the formation of a six-coordinate (6c) low-spin and CO-P420 species in the absence and presence of CO (Figure S1 and S2, panels C and D), respectively. This phenomenon is not uncommon in P450 enzymes and has previously been reported for Mtb CYP51 and CYP121 (24).

Alternatively, we looked at the formation of ferrous-NO complexes by anaerobic reduction of the ferric-NO forms with dithionite. To capture the optical spectra of the possible intermediates in the formation of the final ferrous-NO complexes, the reaction was analyzed using a stopped-flow equipped with a photo-diode detector. For this, the ferric-NO proteins were reacted with dithionite (250  $\mu M$ ), and 200-300 spectra were collected at increasing time scales. Singular

value decomposition and global analysis allowed fitting of the kinetic data for all the proteins to models involving two, three or even four species. For clarity, only the calculated spectra (Figure 5, panels A-D) and their concentration profiles are presented (Figure 5, *insets*). Selected representative real spectra at definite time points for all four proteins are also available and are shown in Figure S3 (supporting material). In addition, the wavelength maxima of all calculated species and derived rates are listed in Tables S6 and S7 (supporting material). As detailed below, the reduction of the ferric-NO forms of our Mtb P450s resulted in the formation of 5c ferrous-NO complexes characterized by a blue-shifted Soret band (389-409 nm) and a subtle peak at ~480 nm. Furthermore, the deduced affinities of our Mtb P450s for \*NO in the ferrous state are extremely high, as evidenced by the lack of CO replacement after flushing the protein samples with Ar for 4 min to get rid of excess \*NO followed by saturation of the protein solutions with 1 atmosphere of CO ( $\approx$  1 mM, at room temperature). Indeed, absolutely no replacement of \*NO by CO has been observed after collecting spectral data for at least 60 min (data not shown).

#### **CYP125**

The spectral data recorded for CYP125 were fitted to model  $A \rightarrow B$  with a slow rate constant  $k = 0.058 \text{ s}^{-1}$  (Table S7, supporting material). As shown in Figure 5A, species A matches perfectly to that of the initial ferric-NO protein, whereas species B corresponds to an unexpected ferrous-NO form characterized by a Soret band at 409 nm. Indeed, the blue-shifted Soret band strongly suggests the formation of a major 5c ferrous-NO species and not the expected 6c ferrous-NO species. The lack of detection of a more red-shifted 6c ferrous-NO species can be explained by a much faster rate of conversion from the 6c to the 5c ferrous-NO compared to that of the very slow reduction of the heme iron by sodium dithionite.

#### **CYP142**

As shown Figure 5B, the reaction of the ferric-NO form of CYP142 with sodium dithionite was also very slow and resulted in the formation of 3 new species. Indeed, the spectral data can be qualitatively described with a model A→B→C, but the addition of a fourth species D gave a much better fit. Similarly to what we saw with CYP125, the reduction of the ferric-NO resulted in the formation of blue-shifted ferrous-NO complexes. Species C is similar to the ferrous-NO observed with CYP125 and is also characterized by a Soret at 409 nm, whereas species B exhibits a Soret centered at 424 nm. We propose that the species B and C originate from two spectrally indistinguishable ferric-NO conformers but with different reduction kinetics. The spectral features of species D are similar those of the ferrous deoxy species described in Figure S1 (supporting material), indicating that the \*NO bound to the protein is very slowly released and scavenged by the excess of sodium dithionite. This last observation indeed supports the idea that the affinity of \*NO for ferrous *Mtb* P450s is high and may inhibit the function of these enzymes *in vivo*.

#### **CYP130**

The spectral data for CYP130 were best fitted to a model A→B→C. As shown in Figure 5C, ferric-NO CYP130 (species A) is converted within 1 s to a species B characterized by a redshifted Soret band at 436 nm and a shoulder at 417 nm. B is not a pure species but is representative of a mixture of 6c ferrous-NO and ferrous deoxy species. For the next 8 s, B decayed to a species C that corresponds to a 5c ferrous-NO form, as evidenced by a blue-shifted Soret band at 388 nm (25) and a subtle peak at ~480 nm (26). Moreover, the low-absorbing and broad Soret band is indicative of some heme destruction, suggesting that the holoprotein also underwent partial denaturation upon reduction.

#### CYP51

The kinetic data for the reduction of ferric-NO CYP51 presented in Figure 5D were fitted with a model consisting of three species. The initial ferric-NO form (species A) reacted rapidly with sodium dithionite to give a putative 5c ferrous-NO form (species B) that is spectrally similar to the 5c ferrous-NO complex of mammalian CYP1A2 characterized by a Soret band at 400 nm (27). This intermediate was then quickly converted to species C, characterized by a Soret band at 396 nm and a shoulder centered at ~375 nm, suggesting that CYP51, like CYP130, underwent partial denaturation and some release of heme.

## Resonance Raman spectroscopy of the ferrous-NO species

Resonance Raman spectroscopy was used to support the proposal that the ferrous-NO complexes of our Mtb P450 enzymes are mostly or completely 5c. The resonance Raman spectra of the ferrous-NO complexes of CYP130 and CYP51 (Figure 6A and B) recorded in the high-frequency region show  $v_4$ ,  $v_3$  and  $v_{10}$  lines at 1375, 1508 and 1645 cm<sup>-1</sup>, respectively. The frequencies of these lines are indicative of a typical 5c ferrous-NO species (25, 28). Furthermore, the binding of NO to the heme iron is confirmed by the high frequency of the  $v_4$  line (1375 cm<sup>-1</sup>). A shoulder at  $\approx$ 1360-1362 cm<sup>-1</sup> is assigned to photo-dissociated products based on the identical frequencies displayed by the  $v_4$  line of the ferrous 6c low-spin form of CYP130 and CYP51 obtained after the reduction of ferric enzymes by sodium dithionite (Raman spectra not shown and Figure S1). On the other hand, the resonance Raman spectra of CYP125 and CYP142 (Figures 6C and D) exhibit  $v_4$ ,  $v_3$  and  $v_{10}$  lines at ~1373, ~1502 and 1638 cm<sup>-1</sup>, respectively. The frequencies of the  $v_3$  and  $v_{10}$  lines are different from those of a typical 5c ferrous-NO complex, near 1508 cm<sup>-1</sup> ( $v_3$ ) and near 1645 cm<sup>-1</sup> ( $v_{10}$ ) (28, 29), respectively. The v<sub>3</sub> line is also different from those of 6c ferrous-NO species of thiolatecoordinated heme proteins, which are typically in the 1497-1499 cm<sup>-1</sup> range (25, 30, 31). The observed frequencies are similar to those displayed by nNOS Trp409 mutants (25), which rather suggests a mixture that contains a majority of a 5c ferrous-NO and a minority of a 6c ferrous-NO species that may not retain the thiolate ligand (32).

## Reaction of the ferrous-NO complexes with O2

As mentioned earlier, the lack of replacement of 'NO by CO indicates that the affinity of the ferrous state for 'NO is extremely high and predicts that 'NO would be a better inhibitor of P450 activity than CO. Therefore, to address the stability of the ferrous-NO complexes under aerobic conditions, we mixed anaerobically prepared NO-bound protein solutions with a buffer solution saturated with O2. Before exposure to O2, the protein samples were first flushed with Ar to remove excess 'NO, thus limiting the potential for chemical modifications of the protein by reactive nitrogen products. Spectra were collected at 1-min intervals for different periods of time and the data are shown in Figure S4 (supporting material). For CYP142, exposure of the 5c ferrous-NO complex to O<sub>2</sub> resulted in relatively fast conversion (less than 7 min) to the ferric state (Figure S4, panel B, supporting material). The oxidation of the ferrous-NO form of CYP125 was even faster and was complete within 2 min (not shown). In contrast, the ferrous-NO complexes of CYP130 and CYP51 reacted very slowly with O<sub>2</sub>, resulting in the formation of only 10% of ferric protein after 12 h (Figure S4, panel A, supporting material). Altogether, these results suggest that the two classes of 5c ferrous-NO complexes have different reactivities. Consequently, the binding of \*NO to the ferrous protein, or reduction of the ferric-NO complex, would result in quasi-irreversible inhibition of CYP130 and CYP51, but in reversible inhibition of CYP125 and CYP142.

## Nitrite reductase activity

'NO is proposed to play an important role in controlling the growth of *Mtb* in its human host but also induces an adaptation program that allows the mycobacteria to survive in a dormant

state. \*NO is very unstable and nitrate is one of the stable breakdown end products, suggesting that when *Mtb* cells enter into dormancy nitrate is available. Furthermore, induction of nitrate reduction activity was recently shown to enhance the survival of *Mtb* cells during inhibition of aerobic respiration (33). One possible dark side of this enhanced nitrate reductase activity would be the release of the more reactive product, nitrite. Indeed, acidification and enzymatic reduction of nitrite leads to a significant production of \*NO. The latter mechanism has been recently shown to be of physiological relevance, as exemplified by the nitrite reductase activity of ferrous myoglobin and its role in the regulation of mitochondrial respiration and blood circulation (34,35).

We thus investigated the possibility that *Mtb* P450 enzymes might be self-inhibited by •NO generated under hypoxic conditions by a nitrite reductase activity. Ferric *Mtb* P450 enzymes were incubated with a physiological concentration of nitrite (100 µM) under strictly anaerobic conditions. The reduction reactions were triggered by the addition of 0.5 mM sodium dithionite. As shown in Figure 7A and B, CYP130 and CYP51 were progressively converted into their respective 5c ferrous-NO forms, as evidenced by the increase of absorbance at 387 or 395 nm. In the case of CYP125 and CYP142, we did not observe any formation of ferrous-NO, but only a slow conversion to their respective ferrous deoxy form (Figure 7C and D). For these two proteins, the lack of accumulation of ferrous-NO complex can be explained by a faster destruction of \*NO by sodium dithionite compared to its formation due to a too slow reduction of the heme (Figure S1, supporting material). These results suggest that: (*1*) heme-thiolate proteins, like imidazole-heme proteins, are capable of \*NO formation by virtue of a nitrite reductase activity; (*2*) nitrite accumulation in *Mtb* cells during hypoxia can constitute an autocatalytically generated source of \*NO that could interfere with normal P450 activities.

## DISCUSSION

•NO is a small gas molecule that can bind to both ferric and ferrous forms of heme-containing enzymes and several lines of evidence indicate that P450 enzymes might be targeted by 'NO *in vivo*. Here, we have studied the interactions between 'NO and four *Mtb* P450 enzymes, CYP125, CYP130, CYP142 and CYP51. Of these, we report the first expression and initial characterization of CYP125 and CYP142. We have used UV-visible absorption spectroscopy and stopped-flow spectrophotometry to investigate the binding of 'NO to these enzymes in their ferric resting state and the reduction of the resulting ferric-NO complexes with sodium dithionite. We have also explored the self-inhibition of these enzymes by virtue of a previously undetected nitrite reductase activity that generates 'NO.

## Binding of 'NO to the ferric form

As shown by the data in Table 1, \*NO binds to the ferric, substrate-free forms of CYP125, CYP142 and CYP51 CYP101 with comparable affinities ( $K_d \le 2 \mu M$ ). This range of concentrations is in good accordance with the steady-state concentrations of \*NO measured in activated macrophages (36). Although CYP130 exhibits a higher  $K_d$  value (Table 1) in the ferric state, its affinity presumably increases dramatically when the heme iron is in its reduced form, as suggested by the resistance of the ferrous-NO complex to oxidation (Figure S4, supporting material) and replacement by CO (not shown).

The rates of combination of \*NO to our four *Mtb* P450s are in good agreement with previous values obtained for other thiolate-ligated hemeproteins, including P450<sub>cam</sub>, CYP1A2, and NOS (Table 1). Indeed, the anionic nature of the proximal thiolate ligand stabilizes the ferric state and increases dramatically the reactivity toward \*NO compared to that of imidazole-ligated hemeproteins like myoglobin (37). However, all these thiolate-ligated proteins still exhibit a wide range of combination rate constants, indicating that other factors also affect the reaction. One of these factors is the increased lability of the leaving water molecule that is coordinated

to the heme. Accordingly, CYP125, which exhibits a much higher content of high-spin heme in its resting state, showed by far the fastest 'NO combination reaction. Moreover, the presence of substrate in the active site has also been shown to negatively affect the dynamics of the reaction with gas ligands by making the protein and the heme pocket more rigid (38). Since we do not know the natural substrate(s) for our enzymes such comparisons cannot be made here.

## Ferrous-nitrosyl complexes

A very high affinity for ferric enzymes contributes only in part to the full inhibitory potential of \*NO. Indeed, as opposed to the coordination of type II ligands that tend to be inhibitors because they stabilize the low reduction potential of P450 and prevent heme reduction and O<sub>2</sub> binding (39), the binding of NO tends to facilitate reduction of the heme group. We have shown here that reduction of the ferricnitrosyl forms of the Mtb P450s carried out chemically does not give rise to formation of stable 6c ferrous-NO species but rather to two distinct classes of 5c ferrous-nitrosyl complexes with different reactivities towards O<sub>2</sub>. Indeed, with the exception of a very small amount of 6c ferrous-NO complex detected with CYP130, no kinetic evidence for the accumulation of a stable 6c ferrous-NO intermediate was observed by UVvisible absorption spectrophotometry, indicating that the Fe-S bond is very labile. Resonance Raman spectroscopy data support the idea that CYP130 and CYP51 form typical 5c ferrous-NO complexes (Figure 6A and B). Indeed, comparisons with other thiolateligated proteins strongly suggest that the ferrous-NO complexes of CYP130 and CYP51 are identical to those of the mammalian CYP1A2, substrate-free nNOS, the heme-thiolate sensor CooA from Rhodospirillum rubrum, the human heme-containing eIF2α kinase, and nitrophorin of the bloodsucking insect Cimex lectularius (Table S8, supporting material) (25,40-42). For the latter protein, structural data confirmed that the Fe-Cys bond was broken and an S-NO adduct was formed with the released proximal Cys (40). It was also shown that the 6c ferrous-NO complex of wild-type nNOS is stable only in the presence of  $H_4B$  or L-arginine; in their absence, the initial 6c ferrous-NO complex converts with time to a 5c ferrous-NO complex characterized by wavelength maxima at 394 nm and ~570 nm (25). So far, identification of the natural substrate for any Mtb P450 remains elusive; however, it is likely that substrate-bound enzymes have altered heme pocket structures that presumably reinforce the proximal thiolate bond and consequently may result in more stable 6c ferrous-NO complexes.

In contrast, the ferrous-nitrosyl complexes of CYP125 and CYP142 are more similar to those observed for the substrate- and cofactor-bound complexes of the W409F and W409Y mutants of nNOS with a more red-shifted Soret band at 409 nm. The Trp residue at position 409 is conserved in all NOS isoforms. The crystal structure data show that the indole nitrogen atom of this Trp residue forms an H-bond with the sulfur atom of the proximal Cys ligand (43,44). Resonance Raman (25) and magnetic circular dichroism spectroscopy (32) indicated that the ferrous-NO complexes of these proteins consist of a mixture of major 5c and minor 6c species. By the use of resonance Raman spectroscopy we also obtained quite similar results for CYP125 and CYP142. Interestingly, it was shown that changing Trp409 to either Phe or Tyr resulted in more active nNOS enzymes (45). This was later explained by the fact that the two mutants do not form as much heme-NO complex during catalysis due to faster decay of their ferrous-NO back to the ferric form in the presence of O<sub>2</sub> (46). Similarly, we observed a higher reactivity of the ferrous-NO species of CYP125 and CYP142 towards O<sub>2</sub>, suggesting that the activity of these two enzymes would be less impaired *in vivo*, compared to that of CYP130 and CYP51.

#### Physiological sources of 'NO

The major source of 'NO responsible for the induction and maintenance of bacilli dormancy in activated macrophages is proposed to be iNOS. In the murine tuberculosis model, it has been shown that genetic disruption of iNOS results in higher risk of dissemination and mortality

after infection with *Mtb* (47,48). The role of \*NO in killing *Mtb* in human cells is more controversial, but there is a growing body of evidence supporting the involvement of \*NO and iNOS (2,49). However, the enzymatic activity of NOS requires oxygen and would be impaired at the low O<sub>2</sub> concentrations presumably found in the granuloma. In this context, it was shown recently that endothelial NOS (eNOS) possesses a nitrite reductase activity capable of delivering \*NO in hypoxic vascular tissues (50). We show here that CYP130 and CYP51 and potentially other thiolate-ligated hemeproteins reduce physiological concentrations of nitrite to \*NO. This was clearly evidenced by the trapping of \*NO by the heme, leading to the formation of ferrous-NO complexes.

#### **Conclusions**

A role for \*NO in the inhibition of P450 activities in dormant *Mtb* cells is conceivable. However, so far, genomic and proteomic studies have not reported any significant impact of cell exposure to \*NO on P450 levels at either the mRNA or protein levels. Instead, the present results suggest that \*NO inhibition may be mediated by the direct formation of heme-NO adducts. Indeed, we show that at least three members of the *Mtb* P450 complement bind \*NO in their ferric state with high affinities. Moreover, the reduction of the ferric-nitrosyl complexes resulted, for CYP130 and CYP51, in the formation of quasi-irreversible 5c ferrous-NO species that barely convert back to the ferric state upon re-exposure to O<sub>2</sub>. In contrast, the ferrous-NO complexes of CYP125 and CYP142 are more labile, indicating that these two enzymes are less susceptible to inhibition. Furthermore, we show that at least two *Mtb* P450s enzymes are capable of reducing nitrite ions to \*NO, resulting in an autoinhibitory process.

## Supplementary Material

Refer to Web version on PubMed Central for supplementary material.

# **Acknowledgements**

This work was supported by National Institutes of Health grant AI074824.

## REFERENCES

- Toossi, Z.; Ellner, JJ. Tuberculosis: Curr. Concepts and Treatment. 2000. Pathogenesis of tuberculosis; p. 19-47.
- Chan ED, Chan J, Schluger NW. What is the role of nitric oxide in murine and human host defense against tuberculosis? Current knowledge. Am. J. Respir. Cell. Mol. Biol 2001;25:606–612. [PubMed: 11713103]
- 3. Flynn JL, Chan J. Immune evasion by *Mycobacterium tuberculosis*: living with the enemy. Curr. Opin. Immunol 2003;15:450–455. [PubMed: 12900278]
- 4. Long R, Light B, Talbot JA. Mycobacteriocidal action of exogenous nitric oxide. Antimicrob. Agents Chemother 1999;43:403–405. [PubMed: 9925545]
- Gow AJ, Foust R, Malcolm S, Gole M, Ischiropoulos H. Biochemical regulation of nitric oxide toxicity. Nitric Oxide and Infection 1999:175–187.
- Brunori M. Nitric oxide, cytochrome-c oxidase and myoglobin. Trends Biochem. Sci 2001;26:21–23.
   [PubMed: 11165512]
- 7. Pfeiffer S, Gorren AC, Schmidt K, Werner ER, Hansert B, Bohle DS, Mayer B. Metabolic fate of peroxynitrite in aqueous solution. Reaction with nitric oxide and pH-dependent decomposition to nitrite and oxygen in a 2:1 stoichiometry. J. Biol. Chem 1997;272:3465–3470. [PubMed: 9013592]
- 8. Nathan C, Shiloh MU. Reactive oxygen and nitrogen intermediates in the relationship between mammalian hosts and microbial pathogens. Proc. Natl. Acad. Sci. U. S. A 2000;97:8841–8848. [PubMed: 10922044]

9. Alexander B. The role of nitric oxide in hepatic metabolism. Nutrition 1998;14:376–390. [PubMed: 9591311]


- Donato MT, Guillen MI, Jover R, Castell JV, Gomez-Lechon MJ. Nitric oxide-mediated inhibition of cytochrome P450 by interferon-gamma in human hepatocytes. J. Pharmacol. Exp. Ther 1997;281:484–490. [PubMed: 9103535]
- 11. Cole ST, Brosch R, Parkhill J, Garnier T, Churcher C, Harris D, Gordon SV, Eiglmeier K, Gas S, Barry CE 3rd, Tekaia F, Badcock K, Basham D, Brown D, Chillingworth T, Connor R, Davies R, Devlin K, Feltwell T, Gentles S, Hamlin N, Holroyd S, Hornsby T, Jagels K, Krogh A, McLean J, Moule S, Murphy L, Oliver K, Osborne J, Quail MA, Rajandream MA, Rogers J, Rutter S, Seeger K, Skelton J, Squares R, Squares S, Sulston JE, Taylor K, Whitehead S, Barrell BG. Deciphering the biology of *Mycobacterium tuberculosis* from the complete genome sequence. Nature 1998;393:537–544. [PubMed: 9634230]
- 12. McLean KJ, Munro AW. Structural biology and biochemistry of cytochrome P450 systems in *Mycobacterium tuberculosis*. Drug Metab. Rev 2008;40:427–446. [PubMed: 18642141]
- Bellamine A, Mangla AT, Nes WD, Waterman MR. Characterization and catalytic properties of the sterol 14alpha-demethylase from Mycobacterium tuberculosis. Proc. Natl. Acad. Sci. U.S.A 1999;96:8937–8942. [PubMed: 10430874]
- 14. Van der Geize R, Yam K, Heuser T, Wilbrink MH, Hara H, Anderton MC, Sim E, Dijkhuizen L, Davies JE, Mohn WW, Eltis LD. A gene cluster encoding cholesterol catabolism in a soil actinomycete provides insight into *Mycobacterium tuberculosis* survival in macrophages. Proc. Natl. Acad. Sci. U. S. A 2007;104:1947–1952. [PubMed: 17264217]
- 15. Chang JC, Harik NS, Liao RP, Sherman DR. Identification of Mycobacterial genes that alter growth and pathology in macrophages and in mice. J. Infect. Dis 2007;196:788–795. [PubMed: 17674323]
- Rengarajan J, Bloom BR, Rubin EJ. Genome-wide requirements for *Mycobacterium tuberculosis* adaptation and survival in macrophages. Proc. Natl. Acad. Sci. U. S. A 2005;102:8327–8332. [PubMed: 15928073]
- 17. Leys D, Mowat CG, McLean KJ, Richmond A, Chapman SK, Walkinshaw MD, Munro AW. Atomic structure of *Mycobacterium tuberculosis* CYP121 to 1.06 A reveals novel features of cytochrome P450. J. Biol. Chem 2003;278:5141–5147. [PubMed: 12435731]
- Ouellet H, Podust LM, de Montellano PR. *Mycobacterium tuberculosis* CYP130: crystal structure, biophysical characterization, and interactions with antifungal azole drugs. J. Biol. Chem 2008;283:5069–5080. [PubMed: 18089574]
- 19. Seward HE, Roujeinikova A, McLean KJ, Munro AW, Leys D. Crystal structure of the *Mycobacterium tuberculosis* P450 CYP121-fluconazole complex reveals new azole drug-P450 binding mode. J. Biol. Chem 2006;281:39437–39443. [PubMed: 17028183]
- 20. Podust LM, Poulos TL, Waterman MR. Crystal structure of cytochrome P450 14alpha -sterol demethylase (CYP51) from *Mycobacterium tuberculosis* in complex with azole inhibitors. Proc. Natl. Acad. Sci. U. S. A 2001;98:3068–3073. [PubMed: 11248033]
- 21. Gegner JA, Dahlquist FW. Signal transduction in bacteria: CheW forms a reversible complex with the protein kinase CheA. Proc. Natl. Acad. Sci. U. S. A 1991;88:750–754. [PubMed: 1992467]
- 22. Omura T, Sato R. The carbon monoxide-binding pigment of liver microsomes. I. Evidence for its hemoprotein nature. J. Biol. Chem 1964;239:2370–2378. [PubMed: 14209971]
- Chartier FJ, Couture M. Stability of the heme environment of the nitric oxide synthase from *Staphylococcus aureus* in the absence of pterin cofactor. Biophys. J 2004;87:1939–1950. [PubMed: 15345570]
- 24. McLean KJ, Dunford AJ, Sabri M, Neeli R, Girvan HM, Balding PR, Leys D, Seward HE, Marshall KR, Munro AW. CYP121, CYP51 and associated redox systems in *Mycobacterium tuberculosis*: towards deconvoluting enzymology of P450 systems in a human pathogen. Biochem. Soc. Trans 2006;34:1178–1182. [PubMed: 17073780]
- 25. Couture M, Adak S, Stuehr DJ, Rousseau DL. Regulation of the properties of the heme-NO complexes in nitric-oxide synthase by hydrogen bonding to the proximal cysteine. J. Biol. Chem 2001;276:38280–38288. [PubMed: 11479310]

26. Yoshimura T, Ozaki T. Electronic spectra for nitrosyl(protoporphyrin IX dimethyl ester)iron(II) and its complexes with nitrogenous bases as model systems for nitrosylhemoproteins. Arch. Biochem. Biophys 1984;229:126–135. [PubMed: 6703691]


- 27. Nakano R, Sato H, Watanabe A, Ito O, Shimizu T. Conserved Glu318 at the cytochrome P450 1A2 distal site is crucial in the nitric oxide complex stability. J. Biol. Chem 1996;271:8570–8574. [PubMed: 8621484]
- Lukat-Rodgers GS, Rodgers KR. Characterization of ferrous FixL-nitric oxide adducts by resonance Raman spectroscopy. Biochemistry 1997;36:4178–4187. [PubMed: 9100012]
- 29. Couture M, Burmester T, Hankeln T, Rousseau DL. The heme environment of mouse neuroglobin. Evidence for the presence of two conformations of the heme pocket. J. Biol. Chem 2001;276:36377–36382. [PubMed: 11473111]
- Deng TJ, Proniewicz LM, Kincaid JR, Yeom H, Macdonald ID, Sligar SG. Resonance Raman studies of cytochrome P450BM3 and its complexes with exogenous ligands. Biochemistry 1999;38:13699– 13706. [PubMed: 10521277]
- 31. Hu S, Kincaid JR. Resonance Raman spectra of the nitric oxide adducts of ferrous cytochrome P450cam in the presence of various substrates. J. Am. Chem. Soc 1991;113:9760–9766.
- 32. Voegtle HL, Sono M, Adak S, Pond AE, Tomita T, Perera R, Goodin DB, Ikeda-Saito M, Stuehr DJ, Dawson JH. Spectroscopic characterization of five- and six-coordinate ferrous-NO heme complexes. Evidence for heme Fe-proximal cysteinate bond cleavage in the ferrous-NO adducts of the Trp-409Tyr/Phe proximal environment mutants of neuronal nitric oxide synthase. Biochemistry 2003;42:2475–2484. [PubMed: 12600215]
- Sohaskey CD. Nitrate enhances the survival of *Mycobacterium tuberculosis* during inhibition of respiration. J. Bacteriol 2008;190:2981–2986. [PubMed: 18296525]
- 34. Hendgen-Cotta UB, Merx MW, Shiva S, Schmitz J, Becher S, Klare JP, Steinhoff HJ, Goedecke A, Schrader J, Gladwin MT, Kelm M, Rassaf T. Nitrite reductase activity of myoglobin regulates respiration and cellular viability in myocardial ischemia-reperfusion injury. Proc. Natl. Acad. Sci. U. S. A 2008;105:10256–10261. [PubMed: 18632562]
- 35. Shiva S, Huang Z, Grubina R, Sun J, Ringwood LA, MacArthur PH, Xu X, Murphy E, Darley-Usmar VM, Gladwin MT. Deoxymyoglobin is a nitrite reductase that generates nitric oxide and regulates mitochondrial respiration. Circ. Res 2007;100:654–661. [PubMed: 17293481]
- 36. Lewis RS, Tamir S, Tannenbaum SR, Deen WM. Kinetic analysis of the fate of nitric oxide synthesized by macrophages *in vitro*. J. Biol. Chem 1995;270:29350–29355. [PubMed: 7493969]
- 37. Franke A, Stochel G, Jung C, Van Eldik R. Substrate binding favors enhanced NO binding to P450cam. J. Am. Chem. Soc 2004;126:4181–4191. [PubMed: 15053607]
- 38. Jung C, Bec N, Lange R. Substrates modulate the rate-determining step for CO binding in cytochrome P450cam (CYP101). A high-pressure stopped-flow study. Eur. J. Biochem 2002;269:2989–2996. [PubMed: 12071963]
- 39. Locuson CW, Hutzler JM, Tracy TS. Visible spectra of type II cytochrome P450-drug complexes: evidence that "incomplete" heme coordination is common. Drug Metab. Dispos 2007;35:614–622. [PubMed: 17251307]
- 40. Weichsel A, Maes EM, Andersen JF, Valenzuela JG, Shokhireva T, Walker FA, Montfort WR. Hemeassisted S-nitrosation of a proximal thiolate in a nitric oxide transport protein. Proc. Natl. Acad. Sci. U. S. A 2005;102:594–599. [PubMed: 15637157]
- 41. Igarashi J, Sato A, Kitagawa T, Yoshimura T, Yamauchi S, Sagami I, Shimizu T. Activation of hemeregulated eukaryotic initiation factor 2alpha kinase by nitric oxide is induced by the formation of a five-coordinate NO-heme complex: optical absorption, electron spin resonance, and resonance Raman spectral studies. J. Biol. Chem 2004;279:15752–15762. [PubMed: 14752110]
- 42. Reynolds MF, Parks RB, Burstyn JN, Shelver D, Thorsteinsson MV, Kerby RL, Roberts GP, Vogel KM, Spiro TG. Electronic absorption, EPR, and resonance Raman spectroscopy of CooA, a COsensing transcription activator from *R. rubrum*, reveals a five-coordinate NO-heme. Biochemistry 2000;39:388–396. [PubMed: 10631000]
- 43. Fischmann TO, Hruza A, Niu XD, Fossetta JD, Lunn CA, Dolphin E, Prongay AJ, Reichert P, Lundell DJ, Narula SK, Weber PC. Structural characterization of nitric oxide synthase isoforms reveals striking active-site conservation. Nat. Struct. Biol 1999;6:233–242. [PubMed: 10074942]

44. Crane BR, Arvai AS, Ghosh DK, Wu C, Getzoff ED, Stuehr DJ, Tainer JA. Structure of nitric oxide synthase oxygenase dimer with pterin and substrate. Science 1998;279:2121–2126. [PubMed: 9516116]

- 45. Adak S, Crooks C, Wang Q, Crane BR, Tainer JA, Getzoff ED, Stuehr DJ. Tryptophan 409 controls the activity of neuronal nitric-oxide synthase by regulating nitric oxide feedback inhibition. J. Biol. Chem 1999;274:26907–26911. [PubMed: 10480900]
- 46. Adak S, Wang Q, Stuehr DJ. Molecular basis for hyperactivity in tryptophan 409 mutants of neuronal NO synthase. J. Biol. Chem 2000;275:17434–17439. [PubMed: 10747960]
- 47. Adams LB, Dinauer MC, Morgenstern DE, Krahenbuhl JL. Comparison of the roles of reactive oxygen and nitrogen intermediates in the host response to *Mycobacterium tuberculosis* using transgenic mice. Tuber. Lung Dis 1997;78:237–246. [PubMed: 10209678]
- 48. MacMicking JD, North RJ, LaCourse R, Mudgett JS, Shah SK, Nathan CF. Identification of nitric oxide synthase as a protective locus against tuberculosis. Proc. Natl. Acad. Sci. U. S. A 1997;94:5243–5248. [PubMed: 9144222]
- 49. Nicholson S, Bonecini-Almeida Mda G, Lapa e Silva JR, Nathan C, Xie QW, Mumford R, Weidner JR, Calaycay J, Geng J, Boechat N, Linhares C, Rom W, Ho JL. Inducible nitric oxide synthase in pulmonary alveolar macrophages from patients with tuberculosis. J. Exp. Med 1996;183:2293–2302. [PubMed: 8642338]
- 50. Gauthier C, van Faassen E, Mikula I, Martasek P, Slama-Schwok A. Endothelial nitric oxide synthase reduces nitrite anions to NO under anoxia. Biochem. Biophys. Res. Commun 2006;341:816–821. [PubMed: 16442076]
- Shiro Y, Fujii M, Iizuka T, Adachi S, Tsukamoto K, Nakahara K, Shoun H. Spectroscopic and kinetic studies on reaction of cytochrome P450nor with nitric oxide. Implication for its nitric oxide reduction mechanism. J. Biol. Chem 1995;270:1617–1623. [PubMed: 7829493]
- 52. Scheele JS, Bruner E, Kharitonov VG, Martasek P, Roman LJ, Masters BS, Sharma VS, Magde D. Kinetics of NO ligation with nitric-oxide synthase by flash photolysis and stopped-flow spectrophotometry. J. Biol. Chem 1999;274:13105–13110. [PubMed: 10224063]
- 53. Abu-Soud HM, Wu C, Ghosh DK, Stuehr DJ. Stopped-flow analysis of CO and NO binding to inducible nitric oxide synthase. Biochemistry 1998;37:3777–3786. [PubMed: 9521697]



**FIGURE 1.** UV-visible absorption spectra of CYP125 (A), CYP142 (B), CYP130 (C) and CYP51 (D). Spectra of the resting ferric (red line), ferric-econazole (green line) and ferric-NO (blue line) forms were recorded at a protein concentration of 10  $\mu$ M in 50 mM potassium phosphate buffer (pH 7.4) containing 0.1 mM EDTA at 23 °C.



**FIGURE 2.** Absorbance-time plots for the binding of \*NO to CYP51 recorded at 433 nm at 23 °C. Ferric CYP51 (2.5  $\mu$ M final) was reacted with 20, 37.5 50, 62.5, 75 and 100  $\mu$ M \*NO.




FIGURE 3. NO concentration dependence of  $k_{\rm obs}$  for the binding of \*NO to Mtb CYP130 (A), CYP51 (B), CYP125 and CYP142 (C) as measured by stopped-flow spectrophotometry. The ferric P450 enzymes (2.5  $\mu$ M final) were reacted with increasing \*NO concentrations at 23 °C (CYP130 and CYP51) or 10 °C (CYP125 and CYP142) in 50 mM potassium phosphate buffer (pH 7.4) containing 0.1 mM EDTA. Plots for CYP125 (circle), and the fast (square) and the slow (diamond) phases of \*NO binding to CYP142 are presented in panel C.




FIGURE 4. 'NO dissociation from CYP125 (A), CYP130 (B), CYP142 (C) and CYP51 (D) ferric-NO complexes. Ferric-NO complexes (5  $\mu$ M protein and 10  $\mu$ M \*NO, after mixing) prepared under strictly anaerobic conditions were reacted with an air-saturated solution of Mb-O<sub>2</sub> (12.5  $\mu$ M, after mixing) at 23 °C. For each experiment, a total of 300 spectra were collected over time using a photodiode array detector. The reaction of oxidation of Mb-O<sub>2</sub> by the \*NO released from P450s was well described using a single exponential function. The kinetics at 433 nm and the fit are shown.





FIGURE 5. Reduction of *Mtb* P450 ferric-nitrosyl complexes by sodium dithionite. Calculated spectra obtained from SVD and global analysis of the data recorded for CYP125 (A), CYP142 (B), CYP130 (C) and CYP51 (D). Ferric-nitrosyl complexes (5 μM protein and 100 μM  $^{\circ}$ NO, after mixing) prepared under strictly anaerobic conditions were reacted with sodium dithionite (250 μM, after mixing) at 23  $^{\circ}$ C. For each experiment, a total of 300 spectra were collected over time using the photodiode array detector. The wavelength maxima of the derived species and the calculated rates are summarized in Tables S6 and S7 (supplemental material), respectively.



**FIGURE 6.** High frequency region of the resonance Raman spectra of the ferrous-NO complexes of CYP130 (A), CYP51 (B), CYP125 (C) and CYP142 (D). All spectra were recorded at 23 °C in 50 mM potassium phosphate buffer (pH 7.4) containing 0.1 mM EDTA. For CYP142 the spectrum was recorded only after completion of the reduction reaction. Stars correspond to laser lines.




FIGURE 7. Nitrite reductase activity of *Mtb* CYP130 (A), CYP51 (B), CYP125 (C), CYP142 (D). The ferric proteins (5  $\mu$ M) were prepared under strictly anaerobic conditions in the presence of physiological concentration of nitrite (100  $\mu$ M). The reaction was initiated by the addition of  $\approx 500~\mu$ M sodium dithionite. Spectra were recorded every minute up to 25-35 min at 23 °C. Insets: time-courses at 417 nm for CYP130, CYP51 and CYP142, and at 390 nm for CYP125. A nitrite reductase activity was observed for CYP130 and CYP51, as evidenced by the formation of their respective 5c ferrous-NO species, whereas CYP125 and CYP142 are slowly converted to their respective ferrous deoxy form.

Table 1
Kinetic parameters of •NO binding to ferric P450 and NOS enzymes

Proteins	$k'_{\text{on}} (\mu \text{M}^{-1} \text{s}^{-1})$	$k_{\rm off}({\rm s}^{\text{-}1})$	$K_{\mathrm{d}}$ ( $\mu\mathrm{M}$ )	References
CYP125	17.1 <sup>a</sup>	11.2 ± 0.1 <sup>b</sup>	0.65	This work
CYP130	0.2	$2.45 \pm 0.02^{\ b}$	12.3	This work
CYP142	3.07	$1.09 \pm 0.01$ <sup>b</sup>	0.36	This work
	1.38		0.79	
CYP51	0.9	$1.90 \pm 0.02^{\ b}$	2.11	This work
CYP101 (P450 <sub>cam</sub> )	0.32	0.35 <sup>c</sup>	1.094	(37)
camphor-free	0.0058			
CYP101 (P450 <sub>cam</sub> )	34.5	1.93 <sup>c</sup>	0.0563	(37)
camphor-bound				
$P450_{nor}$	$26^{d}$	n.d.	-	(51)
neuronal NOS	21	$40^b$	1.905	(52)
(heme domain)				
inducible NOS	$0.059^{d}$		491.5	(53)
(-H <sub>4</sub> B - L-Arg)				

<sup>&</sup>lt;sup>a</sup>For *Mtb* CYP125, the  $k'_{\text{On}}$  was measured at 10 °C.

 $<sup>^</sup>b$  For these P450s, the  $k_{\mbox{off}}$  was measured by using Mb-O2 as a •NO scavenger.

 $<sup>^{</sup>c}$ For *Pseudominas putida* P450<sub>cam</sub>, the  $k_{off}$  was measured by using an excess of [Ru<sup>III</sup>(EDTA)H<sub>2</sub>O] to scavenge •NO.

 $<sup>^</sup>d\mathrm{For}\,\mathit{Fusarium\,oxysporum}$  P450nor and human iNOS, the kinetics parameters were measured at 10 °C.

 $<sup>^{</sup>e}$ For human iNOS, the value of the  $k_{Off}$  derived from the Y-intercept of the plot of association rate ( $k_{ObS}$ ) versus [•NO].